Tuesday 04/March/2025 – 08:50 PM
Engineer Mohamed Shimi, Minister of Public Business Sector, was chaired by the General Assembly of the Holding Company for Medicines, Chemicals and Medical Supplies, in order to adopt the results of the holding of the holding company and its subsidiaries for the fiscal year 2023-2024.
Development of subsidiary companies operating in the pharmaceutical sector
Engineer Mohamed Shimi stressed that the ministry pays great attention to the development of subsidiary companies operating in the pharmaceutical sector, updating production lines and expanding their capabilities, increasing the market share, and introducing modern technologies in manufacturing operations to ensure the quality of the drug and adding new preparations, considering that the drug industry is one of the most important vital sectors, indicating that the ministry continues to provide full support for development and modernization projects to ensure improving production efficiency and contributing to the availability of medicines And medical supplies for citizens in high quality and at reasonable prices.
The Minister explained the importance of adhering to the good manufacturing standards GMP and applying the highest quality standards in all stages of production, noting the need to continue working to increase the production capacity of factories, enhance the capabilities of research, innovation, and the development of products, adhere to the programs and time schedules specified for projects, and to pay attention to training human cadres, improving the work environment, periodic maintenance, and expanding export to foreign markets.
Pharmaceutical Holding Achieving revenues of 7.8 billion pounds .. and 777 million pounds, net profit
The report of the Board of Directors, presented by Dr. Ashraf El-Khouly, the executive director of the Holding Company, revealed that the funded lists of the Holding Company for Medicines for the fiscal year 2023-2024 showed that a revenue of 7.8 billion pounds was achieved at a rate In compatibility projects with good manufacturing requirements, which amounted to about 1.8 billion pounds.
The association reviewed the position of the development projects made by the company, the efforts made to comply with the requirements of the World Health Organization and the Egyptian Drug Authority and the application of good manufacturing requirements, where the first phase of GMP projects was completed and the development of 82 productive plans included compatibility with good manufacturing requirements, and a good manufacturing certificate was obtained by the Egyptian Pharmaceutical Authority for 42 lines so far, and projects included developing production machines Productive areas, water stations, air conditioning system, raw materials, complete product and areas of pharmaceutical raw materials and laboratories.
The position of the projects being implemented in addition to the compatibility with the requirements of good manufacturing, which includes the development of areas and productive lines, including tablets, capsule, drinks, drops, ampoule, ointments and stores, pharmaceutical materials, antiseptics, kidney solutions and intravenous solutions, increased production capabilities and adding new production lines, in Cairo production companies, Alexandria for Medicines, Arab Medicines, Nile, Nile For medicines, Memphis for Medicines, Development of Chemical Industries, Sayed, Victory for Drug Chemicals, Egypt for Medical Products, Development and Raising the Performance of Pharmaceutical Company, as well as partnership projects, including dialysis filters, and available investment opportunities such as the biological preparation industry, insulin and similar vital pharmaceutical preparations, the production of dry pills for inhalation, and inhalation, The hormone manufacturing project and the making of active raw materials.
